Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 31;5(5):CD011680.
doi: 10.1002/14651858.CD011680.pub2.

Interventions for necrotizing soft tissue infections in adults

Camille Hua  1 , Romain Bosc, Emilie Sbidian, Nicolas De Prost, Carolyn Hughes, Patricia Jabre, Olivier Chosidow, Laurence Le Cleach
Affiliations

Interventions for necrotizing soft tissue infections in adults

Camille Hua et al. Cochrane Database Syst Rev. .

Abstract

Background: Necrotizing soft tissue infections (NSTIs) are severe and rapidly spreading soft tissue infections of the subcutaneous tissue, fascia, or muscle, which are mostly caused by bacteria. Associated rates of mortality and morbidity are high, with the former estimated at around 23%, and disability, sequelae, and limb loss occurring in 15% of patients. Standard management includes intravenous empiric antimicrobial therapy, early surgical debridement of necrotic tissues, intensive care support, and adjuvant therapies such as intravenous immunoglobulin (IVIG).

Objectives: To assess the effects of medical and surgical treatments for necrotizing soft tissue infections (NSTIs) in adults in hospital settings.

Search methods: We searched the following databases up to April 2018: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers, pharmaceutical company trial results databases, and the US Food and Drug Administration and the European Medicines Agency websites. We checked the reference lists of included studies and reviews for further references to relevant randomised controlled trials (RCTs).

Selection criteria: RCTs conducted in hospital settings, that evaluated any medical or surgical treatment for adults with NSTI were eligible for inclusion. Eligible medical treatments included 1) comparisons between different antimicrobials or with placebo; 2) adjuvant therapies such as intravenous immunoglobulin (IGIV) therapy compared with placebo; no treatment; or other adjuvant therapies. Eligible surgical treatments included surgical debridement compared with amputation, immediate versus delayed intervention, or comparisons of number of interventions.RCTs of hyperbaric oxygen (HBO) therapy for NSTI were ineligible because HBO is the focus of another Cochrane Review.

Data collection and analysis: We used standard methodological procedures expected by Cochrane. The primary outcome measures were 1) mortality within 30 days, and 2) proportion of participants who experience a serious adverse event. Secondary outcomes were 1) survival time, and 2) assessment of long-term morbidity. We used GRADE to assess the quality of the evidence for each outcome.

Main results: We included three trials randomising 197 participants (62% men) who had a mean age of 55 years. One trial compared two antibiotic treatments, and two trials compared adjuvant therapies with placebo. In all trials, participants concomitantly received standard interventions, such as intravenous empiric antimicrobial therapy, surgical debridement of necrotic tissues, intensive care support, and adjuvant therapies. All trials were at risk of attrition bias and one trial was not blinded.Moxifloxacin versus amoxicillin-clavulanate One trial included 54 participants who had a NSTI; it compared a third-generation quinolone, moxifloxacin, at a dose of 400 mg given once daily, against a penicillin, amoxicillin-clavulanate, at a dose of 3 g given three times daily for at least three days, followed by 1.5 g three times daily. Duration of treatment varied from 7 to 21 days. We are uncertain of the effects of these treatments on mortality within 30 days (risk ratio (RR) 3.00, 95% confidence interval (CI) 0.39 to 23.07) and serious adverse events at 28 days (RR 0.63, 95% CI 0.30 to 1.31) because the quality of the evidence is very low.AB103 versus placebo One trial of 43 randomised participants compared two doses, 0.5 mg/kg and 0.25 mg/kg, of an adjuvant drug, a CD28 antagonist receptor (AB103), with placebo. Treatment was given via infusion pump for 10 minutes before, after, or during surgery within six hours after the diagnosis of NSTI. We are uncertain of the effects of AB103 on mortality rate within 30 days (RR of 0.34, 95% CI 0.05 to 2.16) and serious adverse events measured at 28 days (RR 1.49, 95% CI 0.52 to 4.27) because the quality of the evidence is very low.Intravenous immunoglobulin (IVIG) versus placebo One trial of 100 randomised participants assessed IVIG as an adjuvant drug, given at a dose of 25 g/day, compared with placebo, given for three consecutive days. There may be no clear difference between IVIG and placebo in terms of mortality within 30 days (RR 1.17, 95% CI 0.42 to 3.23) (low-certainty evidence), nor serious adverse events experienced in the intensive care unit (ICU) (RR 0.73 CI 95% 0.32 to 1.65) (low-certainty evidence).Serious adverse events were only described in one RCT (the IVIG versus placebo trial) and included acute kidney injury, allergic reactions, aseptic meningitis syndrome, haemolytic anaemia, thrombi, and transmissible agents.Only one trial reported assessment of long-term morbidity, but the outcome was not defined in the way we prespecified in our protocol. The trial used the Short Form Health Survey (SF36). Data on survival time were provided upon request for the trials comparing amoxicillin-clavulanate versus moxifloxacin and IVIG versus placebo. However, even with data provided, it was not possible to perform survival analysis.

Authors' conclusions: We found very little evidence on the effects of medical and surgical treatments for NSTI. We cannot draw conclusions regarding the relative effects of any of the interventions on 30-day mortality or serious adverse events due to the very low quality of the evidence.The quality of the evidence is limited by the very small number of trials, the small sample sizes, and the risks of bias in the included trials. It is important for future trials to clearly define their inclusion criteria, which will help with the applicability of future trial results to a real-life population.Management of NSTI participants (critically-ill participants) is complex, involving multiple interventions; thus, observational studies and prospective registries might be a better foundation for future research, which should assess empiric antimicrobial therapy, as well as surgical debridement, along with the placebo-controlled comparison of adjuvant therapy. Key outcomes to assess include mortality (in the acute phase of the condition) and long-term functional outcomes, e.g. quality of life (in the chronic phase).

PubMed Disclaimer

Conflict of interest statement

Camille Hua: nothing to declare. Romain Bosc: nothing to declare. Emilie Sbidian: nothing to declare. Nicolas De Prost: nothing to declare. Patricia Jabre: nothing to declare. Olivier Chosidow: "I have received consulting fees from Cardiome Pharma Corporation for a board meeting on dalbavancin; my institution (Hôpital Henri Mondor, Department of Microbiology) has received a research grant from the French Society of Dermatology for a metagenomic study in NSTIs (masters degree)." Laurence Le Cleach: nothing to declare. Carolyn Hughes: nothing to declare

Figures

1
1
Flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Moxifloxacin versus amoxicillin‐clavulanate, Outcome 1 Mortality within 30 days.
1.2
1.2. Analysis
Comparison 1 Moxifloxacin versus amoxicillin‐clavulanate, Outcome 2 Proportion of patients who experienced serious adverse events.
2.1
2.1. Analysis
Comparison 2 AB 103 versus placebo, Outcome 1 Mortality within 30 days.
2.2
2.2. Analysis
Comparison 2 AB 103 versus placebo, Outcome 2 Proportion of patients who experienced serious adverse events.
3.1
3.1. Analysis
Comparison 3 IGIV versus placebo, Outcome 1 Mortality within 30 days.
3.2
3.2. Analysis
Comparison 3 IGIV versus placebo, Outcome 2 Proportion of patients who experienced serious adverse events.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011680

References

References to studies included in this review

Bulger 2014 {published data only}
    1. Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, et al. A novel drug for treatment of necrotizing soft‐tissue infections: A randomized clinical trial. JAMA Surgery 2014;149(6):528‐36. [CENTRAL: CN‐00995333; PUBMED: 24740134] - PubMed
Madsen 2017 {published data only}
    1. Madsen MB, Hjortrup PB, Hansen MB, Lange T, Norrby‐Teglund A, Hyldegaard O, et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo‐controlled trial. Intensive Care Medicine 2017;43(11):1585‐93. [CENTRAL: CN‐01365445; DOI: 10.1007/s00134-017-4786-0; PUBMED: 28421246] - DOI - PubMed
Vick‐Fragoso 2009 {published data only}
    1. Vick‐Fragoso RG, Hernández‐Oliva J, Cruz‐Alcázar CF, Amábile‐Cuevas P, Arvis P, Reimnitz JR, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection 2009;37(5):407‐17. [CENTRAL: CN‐00752976; PUBMED: 19768381] - PubMed

References to studies excluded from this review

Abbar 2014 {published data only}
    1. Abbar M, Janane A, Dakkak Y, Ghadouane M, Ameur A. Combination of hyperbaric oxygen therapy and surgical debridement in management of fournier's gangrene. 34th Congress of the Societe Internationale d'Urologie, SIU 2014 Glasgow United Kingdom. Urology 2014;84(4 Suppl 1):S236‐7. [EMBASE: 71654403]
Danino 2010 {published data only}
    1. Danino AM, Guberman S, Mondie JM, Jebrane A, Servant JM. Calcium polyuronate dressing supplemented with zinc and manganese (trionic) in necrotizing dermohypodermitis of the extremities: a randomized multicentre study. Annals of Burns & Fire Disasters 2010;23(2):95‐101. [PUBMED: 21991205] - PMC - PubMed
Fass 1989 {published data only}
    1. Fass RJ, Plouffe JF, Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):164S‐8S. [PUBMED: 2589361] - PubMed
Huang 2006 {published data only}
    1. Huang WS, Hsieh SC, Hsieh CS, Schoung JY, Huang T. Use of vacuum‐assisted wound closure to manage limb wounds in patients suffering from acute necrotizing fasciitis. Asian Journal of Surgery 2006;29(3):135‐9. [PUBMED: 16877210] - PubMed
Linner 2014 {published data only}
    1. Linner A, Darenberg J, Sjolin J, Henriques‐Normark B, Norrby‐Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: A comparative observational study. Clinical Infectious Diseases 2014;59(6):851‐7. [PUBMED: 24928291] - PubMed
Matejec 2013 {published data only}
    1. Matejec R, Kayser F, Schmal F, Uhle F, Bodeker RH, Maxeiner H, et al. Effects of corticotropin‐releasing hormone on proopiomelanocortin derivatives and monocytic HLA‐DR expression in patients with septic shock. Peptides 2013;47:133‐41. [PUBMED: 23891702] - PubMed
Morelli 2008 {published data only}
    1. Morelli A, Lange M, Ertmer C, Dunser M, Rehberg S, Bachetoni A, et al. Short‐term effects of phenylephrine on systemic and regional hemodynamics in patients with septic shock: a crossover pilot study. Shock 2008;29(4):446‐51. [PUBMED: 17885646] - PubMed
Norrby‐Teglund 2009 {published data only}
    1. Norrby‐Teglund A. Managing group A streptococcal infection: the role of IVIg. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki Finland. Clinical Microbiology and Infection 2009;15:S50. [EMBASE: 70070333]
Solomkin 1986 {published data only}
    1. Solomkin JS, Cocchetto DM. Ceftazidime versus tobramycin plus ticarcillin in the treatment of soft‐tissue infections. Clinical Therapeutics 1986;9(1):123‐34. [PUBMED: 3545476] - PubMed
Souyri 2008 {published data only}
    1. Souyri C, Olivier P, Grolleau S, Lapeyre‐Mestre M, French Network of Pharmacovigilance Centres. Severe necrotizing soft‐tissue infections and nonsteroidal anti‐inflammatory drugs. Clinical & Experimental Dermatology 2008;33(3):249‐55. [PUBMED: 18261144] - PubMed
Subrahmanyam 2004 {published data only}
    1. Subrahmanyam M, Ugane SP. Honey dressing beneficial in treatment of Fournier's gangrene. Indian Journal of Surgery 2004;66(2):75‐7. [CENTRAL: CN‐00645330]
Wong 2004 {published data only}
    1. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Critical Care Medicine 2004;32(7):1535‐41. [PUBMED: 15241098] - PubMed
Xu 2015 {published data only}
    1. Xu X‐P, Cai X‐H, Zhang L, Li X‐H, Liu Z‐H, Pan Y, et al. Clinical efficacy of vacuum sealing drainage in treatment of fournier's gangrene. World Chinese Journal of Digestology 2015;23(2):348‐52.

References to studies awaiting assessment

Darenberg 2003 {published data only}
    1. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind, placebo‐controlled trial. Clinical Infectious Diseases 2003;37(3):333‐40. [PUBMED: 12884156] - PubMed
Tally 1986 {published data only}
    1. Tally FP, Kellum JM, Ho JL, O'Donnell TF, Barza M, Gorbach SL. Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections. Antimicrobial Agents and Chemotherapy 1986;29(2):244‐9. [PUBMED: 3717931] - PMC - PubMed

References to ongoing studies

NCT02469857 {unpublished data only}
    1. NCT02469857. Phase III efficacy and safety study of AB103 in the treatment of patients with necrotizing soft tissue infections (ACCUTE) [Phase III, randomized, double‐blind, placebo‐controlled, parallel group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections. ACCUTE (AB103 clinical composite endpoint study in necrotizing soft tissue infections)]. clinicaltrials.gov/ct2/show/NCT02469857 (First received: 6 June 2015).

Additional references

Adams 1985
    1. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Archives of Internal Medicine 1985;145(6):1020‐3. [MEDLINE: ] - PubMed
Anaya 2005
    1. Anaya DA, McMahon K, Nathens AB, Sullivan SR, Foy H, Bulger E. Predictors of mortality and limb loss in necrotizing soft tissue infections. Archives of Surgery 2005;140(2):151‐7; discussion 158. [MEDLINE: ] - PubMed
Anaya 2007
    1. Anaya DA, Dellinger EP. Necrotizing soft‐tissue infection: diagnosis and management. Clinical Infectious Diseases 2007;44(5):705‐10. [MEDLINE: ] - PubMed
Anglemyer 2014
    1. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database of Systematic Reviews 2014;4:MR000034. - PMC - PubMed
Audureau 2017
    1. Audureau E, Hua C, Prost N, Hemery F, Decousser JW, Bosc R, et al. Mortality of necrotising fasciitis: relative influence of individual and hospital‐level factors, a nationwide multilevel study, France, 2007‐2012. British Journal of Dermatology 2017;177(6):1575‐82. [DOI: 10.1111/bjd.15615; PUBMED: 28452064] - DOI - PubMed
Bilton 1998
    1. Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. American S 1998;64(5):397‐400; discussion 400‐1. [PUBMED: 9585771] - PubMed
Blencowe 2015
    1. Blencowe NS, Brown JM, Cook JA, Metcalfe C, Morton DG, Nicholl J, et al. Interventions in randomised controlled trials in surgery: issues to consider during trial design. Trials 2015;16:392. [PUBMED: 26337522] - PMC - PubMed
Boutron 2008
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Annals of Internal Medicine 2008;148(4):295‐309. [PUBMED: 18283207] - PubMed
Boyer 2009
    1. Boyer A, Vargas F, Coste F, Saubusse E, Castaing Y, Gbikpi‐Benissan G, et al. Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management. Intensive Care Medicine 2009;35(5):847‐53. [PUBMED: 19099288] - PubMed
Bryant 2006
    1. Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal‐muscle injury mediates the binding of Streptococcus pyogenes. Journal of Infectious Diseases 2006;193(12):1685‐92. [PUBMED: 16703512] - PubMed
Carapetis 2014
    1. Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2014;59(3):358‐65. [PUBMED: 24785239] - PubMed
CDC 2012
    1. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, 2010. www.cdc.gov/abcs/reports‐findings/survreports/gas10.html (accessed 29 April 2015).
Chelsom 1994
    1. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994;344(8930):1111‐5. [PUBMED: 7934492] - PubMed
Childers 2002
    1. Childers BJ, Potyondy LD, Nachreiner R, Rogers FR, Childers ER, Oberg KC, et al. Necrotizing fasciitis: a fourteen‐year retrospective study of 163 consecutive patients. American Surgeon 2002;68(2):109‐16. [MEDLINE: ] - PubMed
Chosidow 2001
    1. Chosidow O. Subacute forms of necrotizing fasciitis and necrotizing cellulitis: diagnosis criteria and surgical decision‐making. Annales de Dermatologie et de Vénérologie 2001;128(3 Pt 2):390‐3. [MEDLINE: ] - PubMed
Colledge 2009
    1. Colledge A, Hunter B, Bunkall LD, Holmes EB. Impairment rating ambiguity in the United States: the Utah impairment guides for calculating workers' compensation Impairments. Journal of Korean Medical Science 2009;24(Suppl 2):S232‐41. [MEDLINE: ] - PMC - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011.
Delaney 2008
    1. Delaney A, Angus DC, Bellomo R, Cameron P, Cooper DJ, Finfer S, et al. Bench‐to‐bedside review: the evaluation of complex interventions in critical care. Critical Care 2008;12(2):210. [PUBMED: 18439321] - PMC - PubMed
Dellinger 1981
    1. Dellinger EP. Severe necrotizing soft‐tissue infections. Multiple disease entities requiring a common approach. JAMA 1981;246(15):1717‐21. [MEDLINE: ] - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. [MEDLINE: ] - PubMed
Elliott 1996
    1. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Annals of Surgery 1996;224(5):672‐83. [MEDLINE: ] - PMC - PubMed
Elliott 2000
    1. Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft tissue infections. American Journal of Surgery 2000;179(5):361‐6. [MEDLINE: ] - PubMed
Ellis Simonsen 2006
    1. Ellis Simonsen SM, Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, et al. Cellulitis incidence in a defined population. Epidemiology & Infection 2006;134(2):293‐9. [MEDLINE: ] - PMC - PubMed
Fournier 1883
    1. Fournier AJ. Devastating gangrene of the penis [Gangrene Foudroyante de la verge]. Seminars in Medicine 1883;3:345.
Goh 2014
    1. Goh T, Goh LG, Ang CH, Wong CH. Early diagnosis of necrotizing fasciitis. British Journal of Surgery 2014;101(1):e119‐25. [MEDLINE: ] - PubMed
GRADEpro [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 11 October 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Guidance FDA 2012
    1. Food, Drug Administration. Guidances for industry and investigators on safety reporting requirements for investigational new drug applications and bioavailability/bioequivalence studies, and a small entity compliance guide. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid... (accessed 11 October 2017).
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [PUBMED: 21195583 ] - PubMed
Hasham 2005
    1. Hasham S, Matteucci P, Stanley PR, Hart NB. Necrotising fasciitis. BMJ 2005;330(7495):830‐3. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hsiao 2008
    1. Hsiao CT, Weng HH, Yuan YD, Chen CT, Chen IC. Predictors of mortality in patients with necrotizing fasciitis. American Journal of Emergency Medicine 2008;26(2):170‐5. [MEDLINE: ] - PubMed
Ioannidis 2007
    1. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta‐analyses: a large survey. CMAJ : Canadian Medical Association Journal 2007;176(8):1091‐6. [MEDLINE: ] - PMC - PubMed
Johansson 2010
    1. Johansson L, Thulin P, Low DE, Norrby‐Teglund A. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clinical Infectious Diseases 2010;51(1):58‐65. [MEDLINE: ] - PubMed
Kadri 2017
    1. Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, et al. Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor‐dependent shock: a propensity score‐matched analysis from 130 US hospitals. Clinical Infectious Diseases 2017;64(7):877‐85. [PUBMED: 28034881] - PMC - PubMed
Kaul 1997
    1. Kaul R, McGeer A, Low DE, Green K, Schwartz B. Population‐based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy‐seven cases. Ontario Group A Streptococcal Study. American Journal of Medicine 1997;103(1):18‐24. [MEDLINE: ] - PubMed
Kobayashi 2011
    1. Kobayashi L, Konstantinidis A, Shackelford S, Chan LS, Talving P, Inaba K, et al. Necrotizing soft tissue infections: delayed surgical treatment is associated with increased number of surgical debridements and morbidity. Journal of Trauma‐Injury Infection & Critical Care 2011;71(5):1400‐5. [MEDLINE: ] - PubMed
Korhonen 2000
    1. Korhonen K. Hyperbaric oxygen therapy in acute necrotizing infections with a special reference to the effects on tissue gas tensions. Annales Chirurgiae et Gynaecologiae 2000;89(214):7‐36. [MEDLINE: ] - PubMed
Lamagni 2008
    1. Lamagni TL, Darenberg J, Luca‐Harari B, Siljander T, Efstratiou A, Henriques‐Normark B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. Journal of Clinical Microbiology 2008;46(7):2359‐67. [MEDLINE: ] - PMC - PubMed
Lamb 2015
    1. Lamb LE, Sriskandan S, Tan LK. Bromine, bear‐claw scratch fasciotomies, and the Eagle effect: management of group A streptococcal necrotising fasciitis and its association with trauma. Lancet Infectious Diseases 2015;15(1):109‐21. [PUBMED: 25541175] - PubMed
Le Cleach 2014
    1. Cleach L, Trinquart L, Do G, Maruani A, Lebrun‐Vignes B, Ravaud P, et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD009036.pub2] - DOI - PMC - PubMed
Lepoutre 2011
    1. Lepoutre A, Doloy A, Bidet P, Leblond A, Perrocheau A, Bingen E, et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. Journal of Clinical Microbiology 2011;49(12):4094‐100. [MEDLINE: ] - PMC - PubMed
Levett 2015
    1. Levett D, Bennett MH, Millar I. Adjunctive hyperbaric oxygen for necrotizing fasciitis. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD007937.pub2] - DOI - PMC - PubMed
May 2009
    1. May AK, Stafford RE, Bulger EM, Heffernan D, Guillamondegui O, Bochicchio G, et al. Treatment of complicated skin and soft tissue infections. Surgical Infections 2009;10(5):467‐99. [MEDLINE: ] - PubMed
McClaine 2010
    1. McClaine RJ, Husted TL, Hebbeler‐Clark RS, Solomkin JS. Meta‐analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections. Clinical Infectious Diseases 2010;50(8):1120‐6. [PUBMED: 20210644] - PubMed
McHenry 1995
    1. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft‐tissue infections. Annals of Surgery 1995;221(5):558‐63; discussion 563‐5. [MEDLINE: ] - PMC - PubMed
Norrby‐Teglund 1998
    1. Norrby‐Teglund A, Stevens DL. Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response. Current Opinion in Infectious Diseases 1998;11(3):285‐91. [MEDLINE: ] - PubMed
Norrby‐Teglund 2005
    1. Norrby‐Teglund A, Muller MP, Mcgeer A, Gan BS, Guru V, Bohnen J, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous poly specific immunoglobulin together with a conservative surgical approach. Scandinavian Journal of Infectious Diseases 2005;37(3):166‐72. [MEDLINE: ] - PubMed
Nuwayhid 2007
    1. Nuwayhid ZB, Aronoff DM, Mulla ZD. Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Annals of Epidemiology 2007;17(11):878‐81. [MEDLINE: ] - PMC - PubMed
O'Grady 2007
    1. O'Grady KA, Kelpie L, Andrews RM, Curtis N, Nolan TM, Selvaraj G, et al. The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Medical Journal of Australia 2007;186(11):565‐9. [MEDLINE: ] - PubMed
Park 2009
    1. Park KH, Jung SI, Jung YS, Shin JH, Hwang JH. Marine bacteria as a leading cause of necrotizing fasciitis in coastal areas of South Korea. American Journal of Tropical Medicine & Hygiene 2009;80(4):646‐50. [MEDLINE: ] - PubMed
Pham 2009
    1. Pham TN, Moore ML, Costa BA, Cuschieri J, Klein MB. Assessment of functional limitation after necrotizing soft tissue infection. Journal of Burn Care & Research 2009;30(2):301‐6. [MEDLINE: ] - PMC - PubMed
Phan 2010
    1. Phan HH, Cocanour CS. Necrotizing soft tissue infections in the intensive care unit. Critical Care Medicine 2010;38(9 Suppl):S460‐8. [MEDLINE: ] - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rondinelli 2009
    1. Rondinelli RD. Changes for the new AMA Guides to impairment ratings, 6th Edition: implications and applications for physician disability evaluations. PM & R : the Journal of Injury, Function, and Rehabilitation 2009;1(7):643‐56. [MEDLINE: ] - PubMed
Sarani 2009
    1. Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: current concepts and review of the literature. Journal of the American College of Surgeons 2009;208(2):279‐88. [MEDLINE: ] - PubMed
Sartelli 2014
    1. Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World Journal of Emergency Surgery 2014;9(1):57. [MEDLINE: ] - PMC - PubMed
SFD‐SPILF 2000
    1. The French Society of Dermatology (SFD) and The French Society of infectious Disease (SPILF). Management of erysipelas and necrotizing fasciitis (long text) [Erysipèle et fasciite Nécrosante : Prise en charge]. Annales de Dermatologie et de Vénérologie 2000;127(12):1118‐37. [MEDLINE: ] - PubMed
Stevens 1989
    1. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, et al. Severe group A streptococcal infections associated with a toxic shock‐like syndrome and scarlet fever toxin A. New England Journal of Medicine 1989;321(1):1‐7. [MEDLINE: ] - PubMed
Stevens 2005
    1. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft‐tissue infections. Clinical Infectious Diseases 2005;41(10):1373‐406. [PUBMED: 16231249] - PubMed
Stevens 2014
    1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2014;59(2):e10‐52. [PUBMED: 24973422] - PubMed
Wilkinson 2004
    1. Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Archives of Surgery 2004;139(12):1339‐45. [MEDLINE: ] - PubMed
Wilson 1952
    1. Wilson B. Necrotizing fasciitis. American Surgeon 1952;18(4):416‐31. [MEDLINE: ] - PubMed
Wong 2003
    1. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. Journal of Bone & Joint Surgery ‐ American volume 2003;85‐A(8):1454‐60. [MEDLINE: ] - PubMed

References to other published versions of this review

Hua 2015
    1. Hua C, Bosc R, Sbidian E, Prost N, Jabre P, Chosidow O, et al. Interventions for necrotizing soft tissue infections in adults. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD011680] - DOI - PMC - PubMed

Publication types

LinkOut - more resources